Today: 9 June 2026
Sidus Space stock jumps 17% after $16.2 million share sale as market stays shut for New Year’s Day
1 January 2026
2 mins read

Sidus Space stock jumps 17% after $16.2 million share sale as market stays shut for New Year’s Day

NEW YORK, January 1, 2026, 04:20 ET — Market closed

  • Sidus Space shares ended the last session up about 17% at $3.14 after the company closed a $16.2 million stock offering.
  • The stock swung from $2.48 to $4.20 in the session, with roughly 170 million shares traded.
  • A new Schedule 13G showed CVI Investments and Heights Capital Management held a 7.4% stake.

Shares of Sidus Space Inc (SIDU) rose about 17% to $3.14 in the most recent U.S. session after the company said it closed a $16.2 million public stock offering. The stock traded between $2.48 and $4.20, with volume of roughly 170 million shares.

The move matters now because fresh equity raises can quickly change the risk profile for micro-cap companies that rely on outside financing. The cash can extend runway for operations and manufacturing, but new shares also dilute existing holders by increasing the stock available to trade.

A dilution story is not always a sell signal, though. When shares rise after an offering, it often means the market is focusing on improved liquidity and a clearer near-term funding picture rather than the added share count.

A filing showed the registered direct offering was arranged with ThinkEquity as placement agent, with Sidus agreeing to pay a 7% cash fee and reimburse certain expenses. The company also agreed to issue placement agent warrants — contracts that give the holder the right to buy shares later at a set price — for up to 540,000 shares at an exercise price of $1.875, exercisable immediately and lasting five years, the filing said.

Another filing showed CVI Investments and Heights Capital Management reported beneficial ownership of 4 million shares, or 7.4% of Sidus’ Class A common stock. The Schedule 13G — a disclosure required for investors who hold more than 5% of a public company’s shares — cited about 54.4 million shares outstanding after a recent offering.

The price action left Sidus trading well above the $1.50 offering price, highlighting how quickly sentiment can swing in thinly covered names. That gap can also set up two-way trading as new shareholders manage positions and short-term traders chase momentum.

Sidus describes itself as a space and defense technology company that provides satellite manufacturing and technology integration, along with space-based data and related services.

In its latest quarterly update, the company reported third-quarter revenue of $1.3 million, down 31% from a year earlier, and said the decline reflected a pivot away from legacy services toward newer commercial models.

U.S. equity markets are closed on Thursday for New Year’s Day and are scheduled to reopen on Friday.

Before the next session, investors will weigh a light but market-moving data slate, including initial jobless claims and construction spending due on Friday morning. The next ISM manufacturing report for December is scheduled for Monday, which can steer broader risk appetite and volatility in higher-beta stocks.

On the company calendar, Sidus’ investor relations site lists no upcoming events. With the equity raise now completed, traders will watch for any follow-on filings around the offering, and for the company to post the timing of its next results and business update.

Technically, traders will be watching whether the stock can hold recent gains near Wednesday’s close and whether it revisits last session’s highs, after the wide intraday range underscored elevated volatility. The $1.50 deal price is also likely to remain a reference point for risk-taking and profit-taking.

Stock Market Today

  • Docebo (TSX:DCBO) Valuation Story Shifts Amid Revised Earnings Guidance
    June 9, 2026, 10:40 AM EDT. Docebo's fair value remains at CA$35.97 despite updated financial models, reflecting a recalibration of valuation assumptions. Analysts highlight contrasting bullish views, citing a clear growth story backed by recent revenue guidance raising full-year 2026 estimates to US$271-275 million, against bearish concerns over limited analyst coverage and potential risks. The e-learning software provider forecast revenue of approximately US$65.4-65.6 million for Q1 2026, and US$66.7-66.9 million for Q2. At its Inspire 2026 event, Docebo unveiled a next-generation learning platform and key product updates, signaling strategic progress. Investors should monitor shifting assumptions and sector context amid evolving market narratives.

Latest articles

Autozi Shares Jump 400%, Filing Flags Risks for AZI

Autozi Shares Jump 400%, Filing Flags Risks for AZI

9 June 2026
Autozi Internet Technology shares soared over 400% to $5.69 in early Nasdaq trading after a 10-for-1 share consolidation slashed its share count to about 4.49 million, but the surge contrasts with a 63.1% revenue drop, 82.5% plunge in gross profit, and widened net loss, with the company warning of “substantial doubt” about its ability to continue as a going concern.
Redwire Shares Slip After $500 Million Stock Offering Filed

Redwire Shares Slip After $500 Million Stock Offering Filed

9 June 2026
Redwire Corp shares plunged 6.5% to $17.37 after launching a $500 million at-the-market stock program, raising dilution risks for investors as the company seeks flexible funding despite recent record backlog and strong revenue growth; the drop contrasted with gains at other space stocks, highlighting investor concern over potential share issuance.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

9 June 2026
Nuvalent shares soared 38.9% to $122.93, just below GSK’s $124-a-share cash offer after the $10.6 billion buyout was announced, as investors bet on the deal closing with Nuvalent’s two lead lung-cancer drugs already under FDA review and a 40% premium to the last closing price driving the morning’s merger-arb trade.
Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
Why FICO Stock Is Sliding Today: Fair Isaac Drops in Thin Year-End Trading
Previous Story

Why FICO Stock Is Sliding Today: Fair Isaac Drops in Thin Year-End Trading

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD
Next Story

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Go toTop